Hilary Margaret Kupstas PA

Recommended Articles

• Duchenne Muscular Dystrophy Therapy Receives Rare Pediatric Disease Designation

  Duchenne Muscular Dystrophy is characterized by progressive muscle degeneration paired with weakness.  This is caused by the lack of dystrophin.  This protein is the key to muscles staying strong and uninjured.  This disorder is typically found when a person is very young, as early as three years...

• Treatment for Cholera

  Cholera is a contagious infection that affects mostly the intestines apart from other parts of the body. The infection is known to cause severe effects to its victims, and it has claimed the lives of thousands of people every year. Although the illness is dangerous and severe, somehow not many...

• Fat Injections Can Hinder Mammograms

  Injecting fat from other parts of the body to augment breasts is becoming more popular than the traditional methods used for breast enlargement procedures. Studies have indicated that the injection of fat in the breast tissue can hinder mammograms.Two major studies published in the journal, Plastic...

• What Women with Breast Cancer Can Do About Depression

  Breast cancer impacts millions of women each year. Beyond the physical impact of the disease, breast cancer can present a myriad of other hurdles for patients and women who are in remission.In the United States, women have a 1 in 8 chance of developing breast cancer at some point in her...

• Anti-Tremor Medications for Parkinson's Disease

  IntroductionParkinson’s disease is a chronic and progressive disorder. In this disorder, the movements of the individual are affected. When we say progressive, it means that as time passes by, the symptoms related to the disease tend to worsen. Parkinson’s disease does not have a complete cure...

• FDA Approves Baricitinib for Adults with Active Rheumatoid Arthritis

  On June 1st of 2018, the US Food and Drug Administration (FDA) approved Olumiant (Baricitinib) for the treatment of adults with moderate to severe rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more TNF inhibitor therapies. “We are pleased to provide RA...